ArticleFrontiers in aging neuroscience2026
Isogenic human stem cell models reveal mutation-dependent protective mechanisms of APOE3 Christchurch.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Introduction: Alzheimer's disease (AD) is a progressive neurodegenerative disorder influenced by both causal mutations and genetic modifiers. The rare APOE3 Christchurch (APOE3ch) variant has been associated with delayed disease onset in a familial Alzheimer's disease case, suggesting a potential protective role. However, the mechanisms underlying this protection, particularly across different genetic backgrounds, remain unclear. Methods: We generated isogenic human induced pluripotent stem cell (hiPSC)-derived neural cultures harboring either PSEN1 E280A or amyloid precursor protein duplication (APPdp) mutations, with and without the APOE3ch variant, using prime editing. Neural differentiation, amyloid-beta production, amyloid precursor protein processing, tau phosphorylation and transcriptomic profiles were assessed. Results: APOE3ch did not affect neural differentiation or apolipoprotein E secretion. However, it exhibited mutation-dependent effects on Alzheimer's disease phenotypes. In amyloid precursor protein duplication cultures, APOE3ch significantly reduced amyloid-beta production and shifted processing toward non-amyloidogenic pathways, accompanied by decreased phosphorylated tau. In contrast, in PSEN1 E280A cultures, APOE3ch had minimal impact on amyloid-beta levels but increased non-amyloidogenic processing and altered total tau without affecting phosphorylation. Transcriptomic analysis revealed both shared and mutation-specific effects, with consistent modulation of pathways related to synaptic function, including Wnt and cadherin signaling. Discussion: These findings demonstrate that APOE3ch acts as a context-dependent modifier of Alzheimer's disease pathology, with protective effects varying by genetic background. The variant consistently influences pathways associated with synaptic resilience while differentially modulating amyloid and tau pathology. This work provides mechanistic insight into APOE3ch-mediated protection and highlights the importance of genetic context in developing targeted therapeutic strategies for Alzheimer's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.